[시장보고서]세계의 센트럴 랩 서비스/임상시험 실험실 서비스 시장 : 상별, 서비스 유형별, 치료 분야별, 모달리티별, 최종사용자별, 지역별

세계의 센트럴 랩 서비스/임상시험 실험실 서비스 시장 : 상별, 서비스 유형별, 치료 분야별, 모달리티별, 최종사용자별, 지역별 - 예측(-2030년)

Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030

상품코드 : 1684188 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2025년 03월

페이지 정보 : 영문 311 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,184,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,651,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,828,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,514,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

전 세계 센트럴 랩 서비스/임상시험 실험실 서비스 시장 규모는 2025년 59억 7,000만 달러에서 2030년 81억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 6.5%의 CAGR을 기록할 것으로 예상됩니다.

조사 범위
조사 대상 연도	2024-2030년
기준 연도	2024년
예측 기간	2024-2030년
검토 단위	금액(10억 달러)
부문	상별, 서비스 유형별, 치료 분야별, 모달리티별, 최종사용자별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

이러한 배경에는 신약개발의 채용이 증가하고, 채용이 증가함에 따라 이러한 서비스에 대한 수요가 증가하고 있기 때문입니다. 또한, 헬스케어에 대한 정부 보조금 지원이 증가함에 따라 임상시험의 수가 증가하고 있으며, 이에 따라 중앙연구소의 임상 서비스 시험에 대한 수요도 증가하고 있습니다. 그러나 임상시험 방법과 관련된 높은 비용이 시장의 주요 억제요인으로 작용하고 있습니다. 또한, 숙련된 의료 전문가의 부족과 서비스에 대한 제한된 지식은 시장 성장의 주요 과제입니다. 그러나 2025-2030년 예측 기간 동안에는 시장 성장을 위한 환경이 조성되고 있습니다.

최종사용자별로 센트럴 랩 서비스/임상시험 실험실 서비스 시장은 제약 및 바이오 제약 기업, CROS, 의료기기 기업, 기타 최종사용자로 구분됩니다. 이 중 2024년 센트럴 랩 서비스/임상시험 실험실 서비스 시장에서 제약 및 바이오제약 기업이 61.8%로 가장 큰 시장 점유율을 차지했습니다. 이는 희귀질환의 유병률이 증가하고 있기 때문입니다. 대부분의 제약사들은 고도의 기술을 활용하여 이러한 질환의 치료를 위해 임상시험을 진행하고 있습니다. 따라서 대부분의 기업들은 이러한 서비스를 선호하고 있습니다. 따라서 이러한 질병의 유병률이 증가함에 따라 장기적인 치료의 필요성이 증가함에 따라 센트럴 랩 서비스/임상시험 실험실 서비스 시장의 수요가 증가하고 있습니다.

센트럴 랩 서비스/임상시험실 서비스 시장은 치료 분야별로 종양학, 감염학, 신경학, 심장학, 기타 치료 분야로 구분됩니다. 센트럴 랩 서비스/임상시험 실험실 서비스 시장에서는 암 환자의 증가로 인해 암 분야가 가장 큰 시장 점유율을 차지하고 있습니다. 암 분야 임상시험에서는 임상시험에서 새로운 암 치료제의 유효성과 안전성을 평가하기 위해 바이오마커 검사, 유전체 검사, 종양 프로파일링 등 최신 진단 검사가 필요한 경우가 많습니다. 센트럴 랩은 이러한 서비스를 제공하는 데 있어 중요한 역할을 하며, 검사가 실행 가능하고, 일관성 있고, 여러 기관에서 규제 기준을 준수할 수 있도록 보장합니다. 정밀의료에 대한 관심이 높아짐에 따라, 암 분야는 전문적이고 고품질의 검사실 검사에 대한 요구가 커지면서 센트럴 랩 서비스 시장에서 가장 크고 중요한 분야가 되었습니다.

아시아태평양은 센트럴 랩 서비스/임상시험 실험실 서비스에서 가장 빠르게 성장하는 지역 시장이며, 시장 추정 및 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이는 희귀질환의 유병률 증가와 지역 내 인구 증가에 기인합니다. 아시아태평양에는 일본, 중국, 인도 및 기타 국가가 포함됩니다. 이 중 중국은 2024년 센트럴 랩 서비스/임상시험 실험실 서비스 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이는 제약 및 생명공학 산업의 급속한 성장과 더불어 환자 수가 많고 혁신적인 치료법에 대한 수요가 증가하고 있기 때문입니다. 한국은 헬스케어 인프라의 발전, 임상연구에 대한 투자, 규제 환경의 개선으로 인해 세계 임상시험의 매력적인 거점이 되고 있습니다.

세계의 센트럴 랩 서비스/임상시험실 서비스 시장을 조사했으며, 상별, 서비스 유형별, 치료 분야별, 모달리티별, 최종사용자별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 정리하여 전해드립니다.

소개
시장 역학
고객 비즈니스에 영향을 미치는 동향/혼란
밸류체인 분석
생태계 분석
투자와 자금 조달 시나리오
기술 분석
2025-2026년의 주요 회의와 이벤트
사례 연구 분석
규제 상황
Porter's Five Forces 분석
주요 이해관계자와 구입 기준
AI/생성형 AI가 센트럴 랩 서비스/임상시험 실험실 서비스 시장에 미치는 영향

제6장 센트럴 랩 서비스/임상시험 실험실 서비스 시장, 상별

소개
제I상
제II상
제III상
제IV상

제7장 센트럴 랩 서비스/임상시험 실험실 서비스 시장, 서비스 유형별

소개
안전성 테스트
면역
유전자 검사
응고 검사
병리 검사
바이오마커
동반진단
기타

제8장 센트럴 랩 서비스/임상시험 실험실 서비스 시장, 치료 분야별

소개
종양
감염증
신경
심장병
기타

제9장 센트럴 랩 서비스/임상시험 실험실 서비스 시장, 모달리티별

소개
저분자
생물학
세포 및 유전자 치료
의료기기 및 체외진단용 기기

제10장 센트럴 랩 서비스/임상시험 실험실 서비스 시장, 최종사용자별

소개
제약·바이오의약품 기업
임상 연구 조직
의료기기 기업
기타

제11장 센트럴 랩 서비스/임상시험 실험실 서비스 시장, 지역별

소개
북미
- 북미의 거시경제 전망
- 미국
- 캐나다
유럽
- 유럽의 거시경제 전망
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타
아시아태평양
- 아시아태평양의 거시경제 전망
- 일본
- 중국
- 인도
- 기타
라틴아메리카
중동 및 아프리카

제12장 경쟁 구도

개요
주요 진출 기업 전략/강점
매출 분석, 2020-2024년
시장 점유율 분석, 2024년
기업 가치 평가와 재무 지표
브랜드/제품 비교
기업 평가 매트릭스 : 주요 진출 기업, 2024년
기업 평가 매트릭스 : 스타트업/중소기업, 2024년
경쟁 시나리오

제13장 기업 개요

주요 진출 기업
- THERMO FISHER SCIENTIFIC INC.
- IQVIA
- ICON PLC
- CHARLES RIVER LABORATORIES
- LABCORP
- QUEST DIAGNOSTICS
- MEDPACE
- FRONTAGE LABS
- SGS SOCIETE GENERALE DE SURVEILLANCE SA
- EUROFINS SCIENTIFIC
- REPROCELL INC.
- ACM GLOBAL LABORATORIES
기타 기업
- WORLDWIDE CLINICAL TRIALS
- VERSITI
- CTI CLINICAL TRIAL & CONSULTING
- CLARITY LABORATORIES, INC
- NOVOTECH
- ARUP LABORATORIES
- PRECISION MEDICINE GROUP
- BIOAGILYTIX LABS
- CERBA HEALTHCARE
- ALMAC GROUP
- MLM MEDICAL LABS
- SALVUS BIORESEARCH SOLUTIONS LLP
- UNILABS

제14장 부록

ksm

영문 목차

영문목차

The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	Phase, Service Type, Therapeutic Area, Application,End User, and Region
Regions covered	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.

"The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period."

Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.

"The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market."

Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.

"Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region."

The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
By Designation: C-level-25%, Director-level-30% and Others-45%
By Region: North America-40%, Europe-25%, Asia Pacific-20%, Latin America- 10%, and Middle east and Africa - 5%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Societe Generale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).

Research Coverage

This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

Analysis of Key divers (Increasing number of clinical trials, increasing investments in research & development, growing prevalence of rare diseases), restraints (High cost associated with clinicaltrials, Shortage of skilled professionals), opportunity (Emerging markets worldwide, decentralized and virtual clinical trials), Challenge (regulatory complexities, limited patient diversity and cybersecurity or intellectual property concerns)
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the central lab services/clinical trial lab services market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the central lab services/clinical trial lab services market
Market Development: Comprehensive information on lucrative emerging regions
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Primary sources
  - 2.1.2.2 Key industry insights
  - 2.1.2.3 Key data from primary sources
  - 2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
- 2.2.1 BOTTOM-UP APPROACH
  - 2.2.1.1 Approach 1: Company revenue estimation approach
  - 2.2.1.2 Approach 2: Presentations of companies and primary interviews
  - 2.2.1.3 Approach 3: Primary interviews
  - 2.2.1.4 Growth forecast
  - 2.2.1.5 CAGR projections
- 2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
- 2.4.1 STUDY-RELATED ASSUMPTIONS
- 2.4.2 PARAMETRIC ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW
4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER AND COUNTRY
4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY
4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Increasing number of clinical trials
  - 5.2.1.2 Rising investments in research & development
  - 5.2.1.3 Growing prevalence of rare diseases
  - 5.2.1.4 Favorable government initiatives
- 5.2.2 RESTRAINTS
  - 5.2.2.1 High costs associated with clinical trials
  - 5.2.2.2 Shortage of skilled professionals
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Emerging markets worldwide
  - 5.2.3.2 Decentralized and virtual clinical trials
- 5.2.4 CHALLENGES
  - 5.2.4.1 Regulatory complexities
  - 5.2.4.2 Limited patient diversity
  - 5.2.4.3 Cybersecurity and intellectual property concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 VALUE CHAIN ANALYSIS
- 5.4.1 RESOURCE ACQUISITION AND PREPARATION
- 5.4.2 CLINICAL TRIAL EXECUTION
- 5.4.3 DATA REPORTING AND RESULT SUBMISSION
- 5.4.4 PROMOTION AND REGULATORY FILING
5.5 ECOSYSTEM ANALYSIS
5.6 INVESTMENT AND FUNDING SCENARIO
5.7 TECHNOLOGY ANALYSIS
- 5.7.1 KEY TECHNOLOGIES
  - 5.7.1.1 Enzyme-linked immunosorbent assay
- 5.7.2 ADJACENT TECHNOLOGIES
  - 5.7.2.1 Next-generation sequencing
5.8 KEY CONFERENCES AND EVENTS, 2025-2026
5.9 CASE STUDY ANALYSIS
- 5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)
5.10 REGULATORY LANDSCAPE
- 5.10.1 REGULATORY FRAMEWORK
  - 5.10.1.1 North America
  - 5.10.1.2 Europe
  - 5.10.1.3 Asia Pacific
  - 5.10.1.4 Rest of the World
- 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER'S FIVE FORCES ANALYSIS
- 5.11.1 THREAT OF NEW ENTRANTS
- 5.11.2 THREAT OF SUBSTITUTES
- 5.11.3 BARGAINING POWER OF SUPPLIERS
- 5.11.4 BARGAINING POWER OF BUYERS
- 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.12.2 BUYING CRITERIA
5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
- 5.13.1 INTRODUCTION
- 5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
- 5.13.3 AI USE CASES
- 5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM

6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE

6.1 INTRODUCTION
6.2 PHASE I
- 6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH
6.3 PHASE II
- 6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET
6.4 PHASE III
- 6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET
6.5 PHASE IV
- 6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH

7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE

7.1 INTRODUCTION
7.2 SAFETY TESTING
- 7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH
7.3 IMMUNOLOGY
- 7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH
7.4 GENETIC TESTING
- 7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET
7.5 COAGULATION TESTING
- 7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH
7.6 PATHOLOGY TESTING
- 7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH
7.7 BIOMARKERS
- 7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH
7.8 COMPANION DIAGNOSTICS
- 7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET
7.9 OTHER TESTS

8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA

8.1 INTRODUCTION
8.2 ONCOLOGY
- 8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH
8.3 INFECTIOUS DISEASES
- 8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH
8.4 NEUROLOGY
- 8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH
8.5 CARDIOLOGY
- 8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
8.6 OTHER THERAPEUTIC AREAS

9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY

9.1 INTRODUCTION
9.2 SMALL MOLECULES
- 9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH
9.3 BIOLOGICS
- 9.3.1 MONOCLONAL ANTIBODIES
  - 9.3.1.1 Growing advancements in antibody engineering to drive market
- 9.3.2 VACCINES
  - 9.3.2.1 Increasing investments in vaccine development to favor growth
- 9.3.3 OTHER THERAPEUTIC PRODUCTS
9.4 CELL & GENE THERAPY
- 9.4.1 OUTSOURCING TREND TO FAVOR GROWTH
9.5 MEDICAL DEVICES & IVD DEVICES
- 9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET

10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER

10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
10.3 CLINICAL RESEARCH ORGANIZATIONS
- 10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
10.4 MEDICAL DEVICE COMPANIES
- 10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
10.5 OTHER END USERS

11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.2.2 US
  - 11.2.2.1 Increasing clinical trials to support growth
- 11.2.3 CANADA
  - 11.2.3.1 Rising incidence of chronic diseases to advance growth
11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.3.2 GERMANY
  - 11.3.2.1 Increasing healthcare expenditure to intensify growth
- 11.3.3 FRANCE
  - 11.3.3.1 Growing investments in life sciences sector to boost market
- 11.3.4 UK
  - 11.3.4.1 High number of oncology clinical trials to facilitate growth
- 11.3.5 ITALY
  - 11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth
- 11.3.6 SPAIN
  - 11.3.6.1 Emerging biotech companies to bolster growth
- 11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.4.2 JAPAN
  - 11.4.2.1 Growing demand for drug development to propel market
- 11.4.3 CHINA
  - 11.4.3.1 Booming pharmaceutical industry to drive market
- 11.4.4 INDIA
  - 11.4.4.1 Increasing regulatory reforms to foster growth
- 11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
- 11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH
- 11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
- 11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET
- 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 12.7.1 STARS
- 12.7.2 EMERGING LEADERS
- 12.7.3 PERVASIVE PLAYERS
- 12.7.4 PARTICIPANTS
- 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 12.7.5.1 Company footprint
  - 12.7.5.2 Region footprint
  - 12.7.5.3 Product type footprint
  - 12.7.5.4 Therapeutic area footprint
  - 12.7.5.5 Phase footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 12.8.1 PROGRESSIVE COMPANIES
- 12.8.2 RESPONSIVE COMPANIES
- 12.8.3 DYNAMIC COMPANIES
- 12.8.4 STARTING BLOCKS
- 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
  - 12.8.5.1 Detailed list of key startups/SMEs
  - 12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT LAUNCHES
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

13.1 KEY PLAYERS
- 13.1.1 THERMO FISHER SCIENTIFIC INC.
  - 13.1.1.1 Business overview
  - 13.1.1.2 Products/Services offered
  - 13.1.1.3 Recent developments
    - 13.1.1.3.1 Product launches
    - 13.1.1.3.2 Deals
    - 13.1.1.3.3 Expansions
  - 13.1.1.4 MnM view
    - 13.1.1.4.1 Key strengths
    - 13.1.1.4.2 Strategic choices
    - 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 IQVIA
  - 13.1.2.1 Business overview
  - 13.1.2.2 Products/Services offered
  - 13.1.2.3 Recent developments
    - 13.1.2.3.1 Product launches
    - 13.1.2.3.2 Deals
  - 13.1.2.4 MnM view
    - 13.1.2.4.1 Right to win
    - 13.1.2.4.2 Strategic choices
    - 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 ICON PLC
  - 13.1.3.1 Business overview
  - 13.1.3.2 Products/Services offered
  - 13.1.3.3 Recent developments
    - 13.1.3.3.1 Product launches
    - 13.1.3.3.2 Deals
  - 13.1.3.4 MnM view
    - 13.1.3.4.1 Right to win
    - 13.1.3.4.2 Strategic choices
    - 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 CHARLES RIVER LABORATORIES
  - 13.1.4.1 Business overview
  - 13.1.4.2 Products/Services offered
  - 13.1.4.3 Recent developments
    - 13.1.4.3.1 Deals
    - 13.1.4.3.2 Expansions
  - 13.1.4.4 MnM view
    - 13.1.4.4.1 Right to win
    - 13.1.4.4.2 Strategic choices
    - 13.1.4.4.3 Weaknesses and competitive threats
- 13.1.5 LABCORP
  - 13.1.5.1 Business overview
  - 13.1.5.2 Products/Services offered
  - 13.1.5.3 Recent developments
    - 13.1.5.3.1 Product launches
    - 13.1.5.3.2 Deals
    - 13.1.5.3.3 Expansions
    - 13.1.5.3.4 Other developments
  - 13.1.5.4 MnM view
    - 13.1.5.4.1 Key strengths
    - 13.1.5.4.2 Strategic choices
    - 13.1.5.4.3 Weaknesses and competitive threats
- 13.1.6 QUEST DIAGNOSTICS
  - 13.1.6.1 Business overview
  - 13.1.6.2 Products/Services offered
  - 13.1.6.3 Recent developments
    - 13.1.6.3.1 Deals
- 13.1.7 MEDPACE
  - 13.1.7.1 Business overview
  - 13.1.7.2 Products/Services offered
  - 13.1.7.3 Recent developments
    - 13.1.7.3.1 Expansions
- 13.1.8 FRONTAGE LABS
  - 13.1.8.1 Business overview
  - 13.1.8.2 Products/Services offered
- 13.1.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA
  - 13.1.9.1 Business overview
  - 13.1.9.2 Products/Services offered
  - 13.1.9.3 Recent developments
    - 13.1.9.3.1 Deals
- 13.1.10 EUROFINS SCIENTIFIC
  - 13.1.10.1 Business overview
  - 13.1.10.2 Products/Services offered
  - 13.1.10.3 Recent developments
    - 13.1.10.3.1 Deals
- 13.1.11 REPROCELL INC.
  - 13.1.11.1 Business overview
  - 13.1.11.2 Products/Services offered
  - 13.1.11.3 Recent developments
    - 13.1.11.3.1 Deals
- 13.1.12 ACM GLOBAL LABORATORIES
  - 13.1.12.1 Business overview
  - 13.1.12.2 Products/Services offered
  - 13.1.12.3 Recent developments
    - 13.1.12.3.1 Deals
13.2 OTHER PLAYERS
- 13.2.1 WORLDWIDE CLINICAL TRIALS
- 13.2.2 VERSITI
- 13.2.3 CTI CLINICAL TRIAL & CONSULTING
- 13.2.4 CLARITY LABORATORIES, INC
- 13.2.5 NOVOTECH
- 13.2.6 ARUP LABORATORIES
- 13.2.7 PRECISION MEDICINE GROUP
- 13.2.8 BIOAGILYTIX LABS
- 13.2.9 CERBA HEALTHCARE
- 13.2.10 ALMAC GROUP
- 13.2.11 MLM MEDICAL LABS
- 13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP
- 13.2.13 UNILABS

14 APPENDIX

14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS